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This report from the Tuberculosis Chemotherapy Centre, Madras, describes theprogress,
over a 5-year period, of 341 patients with newly diagnosed, sputum-positive tuberculosis. All
the patients were treated on a domiciliary basis. In the first year, the patients received,
on the basis of random allocation, a standard regimen of isoniazid plus PAS or 1 of
3 regimens of isoniazid alone. Previous reports have shown that the response in the first
year was substantially superior with the standard regimen, and that the bacteriological
relapse rates in the second year were fairly similar for the 4 regimens. The findings in
the present report extend the latter conclusion to the end of 5 years. Further, when con-
sidered together with the findings in an earlier study, they have shown that isoniazid,
given as maintenance chemotherapy in the second year, was highly effective in preventing
bacteriological relapse in patients who, at 1 year, had bacteriologically quiescent disease
and no residual cavitation ; the effect was, however, less marked in patients with residual
cavitation at 1 year.
Patients who were clear-cut failures of the allocated chemotherapy and those who had
a bacteriological relapse in the second or subsequent years were usually re-treated with
streptomycin plus PAS or streptomycin plus pyrazinamide, and if this was ineffective,
with cycloserine plus thioacetazone or cycloserine plus ethionamide.
Considering the findings over the 5-year period for all patients, 16 died from non-
tuberculous causes and 1 took his discharge prematurely. Of the remainder, 86% had
bacteriologically quiescent disease at 5 years, 6 % had bacteriologically active disease
and 8 % had died of tuberculosis. These findings confirm the value of well-organized
domiciliary chemotherapy, which was established by an earlier report from the Centre,
and are particularly encouraging for developing countries such as India, where tuberculosis
is a major problem and resources are limited.
An earlier publication from the Tuberculosis
Chemotherapy Centre, Madras (1960), reported a
controlled comparison, for a year, of 3 regimens of
isoniazid alone with a standard regimen of isoniazid
plus p-aminosalicylic acid (PAS) in the domiciliary
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treatment of patients with pulmonary tuberculosis.
It was found that isoniazid plus PAS was the best
regimen and that isoniazid alone in a daily dosage
of 400 mg was more effective in 1 dose than in 2,
divided, doses. The progress in the second year of
certain categories of these patients has already been
reported by Velu et al. (1961a) and Ramakrishnan
et al. (1962). The present report describes the pro-
gress in the second to fifth years of all the patients
originally admitted to the comparison, and their
disease status at 5 years.
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I. PLAN AND CONDUCT OF THE STUDY
CHEMOTHERAPY DURING THE 5-YEAR PERIOD 3-monthly intervals in the third, fourth and fifth
In the first year, patients were allocated at random
to 1 of 4 daily oral regimens. The drug dosage was
related to the patient’s weight (for details, see Tuber-
culosis Chemotherapy Centre, Madras, 1960). For
instance, for a patient weighing 100 lb (45.4 kg), the
details were as follows:
Regimen Drug and daily dosage
PH Isoniazid 200 mg plus sodium PAS 10 g, given
together in cachets in 2, divided, doses
HI-1 Isoniazid alone, 400 mg, in a single dose
HI-2 Isoniazid alone, 400 mg, in 2, divided, doses
H Isoniazid alone, 200 mg, in 2, divided, doses
The mean daily dosage of isoniazid at the start of
years. The planned intensity of bacteriological exam-
inations is set out in Table 1. The standard pro-
cedure was to obtain 14 specimens in the second
year, 9 in the third, 9 in the fourth and 11 in the
fifth year. Extra specimens were collected if a posi-
tive culture was obtained. An isoniazid sensitivity
test was set up at each of these examinations if a
positive culture was obtained. The techniques em-
ployed for smear and culture examination and sen-
TABLE 1
PLANNED INTENSITY OF BACTERIOLOGICAL
EXAMINATIONS FOR PATIENTS WITH
BACTERIOLOGICALLY QUIESCENT DISEASE
chemotherapy was 4.6 mg/kg of body-weight for the
PH series, 8.7 mg/kg for the HI-1 and the HI-2 series
and 4.5 mg/kg for the H series. The mean daily Year
dosage of PAS (for the PH series) was 0.23 g/kg.
The treatment policy in the second year for
patients with bacteriologically quiescent disease at
2
1 year (defined on page 3) has been fully described
by Velu et al. (1961a). In brief, the patients were
allocated at random to treatment in the second year
with isoniazid alone (approximately 4.5 mg/kg of
body-weight daily, in a single tablet) or to a pla-
cebo-calcium gluconate (500 mg daily, in a single
tablet). During the third year, half (selected at 3
random) of the patients treated with isoniazid in
the second year continued to receive the drug;
all the remaining patients received the placebo.    
All patients received the placebo in the fourth year
and no medicament in the fifth year. However,
chemotherapy was prescribed in a few instances on 4
account of a bacteriological relapse; the numbers
involved and the details are presented on pages 4-9.
The policy was to treat all patients on a domiciliary
basis.
The treatment prescribed to patients with disease
of bacteriologically doubtful status at 1 year and
to those with bacteriologically active disease at
1 year is described on page 9.
5
INVESTIGATIONS IN THE SECOND, THIRD,
FOURTH AND FIFTH YEARS
specimens during the 4-year period of 43
Patients with bacteriologically quiescent disease at follow-up
1 year were assessed clinically and radiographically
at monthly intervals in the second year and at
a For the methods of obtaining the specimens, see Velu
et al. (1961c).
Month
13-23
24
27, 30 and 33
36
39, 42 and 45
48
51, 54 and 57
59 ½
60
AT 1 YEAR
Type and no. of
specimens a
1 collection specimen or
a pair of laryngeal
swabs
2 collection specimens
and a pair of laryngeal
swabs
1 collection specimen and
a pair of laryngeal
swabs
2 collection specimens
and a pair of laryngeal swabs
1 collection specimen and
a pair of laryngeal swabs
2 collection specimens
and a pair of laryngeal
swabs
1 collection specimen and
a pair of laryngeal
swabs
1 collection specimen and
a supervised spot
specimen
2 collection specimens
and a pair of laryngeal
swabs
Total no. of.
specimens
14
9
I
9
11
I
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sitivity tests, the details of the grading of smear
and culture results, and the definition of isoniazid
resistance have all been described elsewhere (Tuber-
culosis Chemotherapy Centre, Madras, 1960).
Patients with bacteriologically active or relapsed
disease were assessed monthly throughout the period
they were receiving chemotherapy. The monthly
examinations included a chest radiograph, examina-
tion by smear and culture of 2 collection specimens
of sputum, examination by culture of a pair of
laryngeal swabs, and tests of sensitivity to the drugs
the patients were receiving using techniques des-
cribed previously (Tuberculosis Chemotherapy Cen-
tre, Madras, 1960; Angel et al., 1963; Rama-
krishnan et al., 1967).
COLLAPSE THERAPY AND RESECTION
The policy was not to use collapse therapy or
resection. In the event, 3 patients had surgical
treatment (1 had a thoracoplasty, a second a plomb-
age followed by a thoracoplasty, and the third a
lobectomy).
CHANGE OF TREATMENT ON ACCOUNT
OF RADIOGRAPHIC DETERIORATION
When the Centre’s physicians considered that a
definite radiographic deterioration had occurred,
and that it persisted despite a course of penicillin,
the full radiographic series was shown to an indepen-
dent assessor (Dr K. S. Sanjivi), who decided whether
a change of treatment was necessary.
DEFINITIONS USED IN THIS REPORT
At 1 year
Bacteriologically quiescent disease. All cultures (usu-
ally a total of 7-9) negative at 10, 11 and 12 months.
Disease of bacteriologically doubtful status. All
cultures negative at 3 or more consecutive monthly
examinations, but a single positive culture at 10,
11 or 12 months.
Bacteriologically active disease.
(a) A definite radiographic or serious clinical dete-
rioration in the presence of a positive sputum, which
necessitated a change of chemotherapy during the
first year; or
(b) Cultures never all negative at 3 consecutive
monthly examinations; or
(c) All cultures negative at 3 or more consecutive
monthly examinations, but a total of 2 or more
positive cultures at 10, 11 and 12 months.
During the second, third, fourth and fifth years
Isolated positive culture. A single positive culture,
preceded by culture negativity for a 6-month period
and succeeded by culture negativity for a 6-month
period.
Bacteriological relapse. Two or more posi-
tive cultures in a 6-month period. This meant 2 or
more positive cultures in 7 consecutive monthly
examinations in the second year, or in 3 consecutive
3-monthly examinations in the subsequent years.
At 5 years
Bacteriologically quiescent disease. 1 All cultures
(usually a total of 7-9) negative from 54 to 60 months,
inclusive.
Bacteriologically active disease. A total of 2 or
more positive cultures from 54 to 60 months,
inclusive.
II. CLASSIFICATION OF PATIENTS AND PLAN OF THE REPORT
CLASSIFICATION OF PATIENTS (Tuberculosis Chemotherapy Centre, Madras, 1960).
The main analysis of the findings in the first year
Of 341 patients who were admitted to the study, (Tuberculosis Chemotherapy Centre, Madras, 1960)
96 were allocated to the PH, 75 to the HI-1, 75 to concerned the remaining 315 patients (90 PH,
the HI-2 and 95 to the H regimen (Table 2). 70 HI-1, 68 HI-2, 87 H) who (1) had cultures
Altogether, 26 patients were excluded from the
main analysis, 22 on account of isoniazid resistance
1 Included in this category are 12 patients (2 PH, 1 HI-l,
on admission and 4 for miscellaneous reasons
3 HI-2, 6 H), each of whom produced 1 positive culture between
54 and 60 months.
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TABLE 2
CLASSIFICATION OF PATIENTS IN THE PRESENT REPORT
Regimen
PH  HI-1  HI-2  H
I I I
(1) Bacteriologically quiescent disease 74 43 37 38 192 III
(2) Disease of bacteriologically doubtful status
4 4 1 0 9 IV
Patients included in the
main analysis in the first (3) Bacteriologically active disease 7 17 27 45 96 V
year, according to the
classificationof their dis- (4) Change of treatment due to drug toxicity 2 5 1 0 8 VI
ease status at 1 year
(5) Death 3 1 2 4 10 –
Total 90 70 68 87 315
(1) lsoniazid-resistant organisms on
6 3 7 6 22
Patients excluded from
VII
the main analysis in the (2) Miscellaneous reasons 0 2 0 2 4
first year
Total 6 5 7 8 26
All patients admitted to the study 96 75 75 95 341 VIII
sensitive to isoniazid on admission, (2) had had no
previous chemotherapy (apart from 11 who had
received up to 2 weeks of chemotherapy), and (3)
had received the allocated chemotherapy for 12
months (apart from minor variations), unless they
died or had a change of chemotherapy because of
tuberculous deterioration or major toxicity. At
1 year, 192 of these patients had bacteriologically
quiescent disease, 9 had disease of bacteriologically
doubtful status and 96 had bacteriologically active
disease; of the remainder, 8 had had their chemo-
therapy changed in the first year on account of drug
toxicity and 10 had died (5 of tuberculosis and 5 of
non-tuberculous causes).
PLAN OF THE REPORT
The plan of the report is set out in Table 2.
The progress in the second, third, fourth and fifth
years is described in Section III for patients with
bacteriologically quiescent disease at 1 year, in Sec-
tion IV for those with disease of bacteriologically
doubtful status at 1 year, in Section V for those
with bacteriologically active disease at 1 year, and
in Section VI for patients whose treatment was
changed during the first year on account of drug
toxicity. Section VII reports the progress of the
patients excluded from the main analysis, and Sec-
tion VIII summarizes the disease status at 5 years
of all the 341 patients admitted to the study.
III. PROGRESS DURING A 4-YEAR PERIOD OF FOLLOW-UP OF PATIENTS
WITH BACTERIOLOGICALLY QUIESCENT DISEASE AT 1 YEAR
Of the 192 patients with bacteriologically quiescent Of the remaining 180 patients (69 PH, 41 HI-l,
disease at 1 year, 11 (4 PH, 2 HI-1, 1 HI-2, 4 H) 36 HI-2, 34 H), 93 were allocated to isoniazid alone
were not allocated at random to treatment in the in the second year (isoniazid series) and 87 to cal-
second year for reasons given by Velu et al. (1961a). cium gluconate (placebo series). On the basis of a
Another patient (PH) had treatment restarted be- postero-anterior chest radiograph and tomograms,
cause she developed tuberculous lymphadenitis. The 54 of these were classified by an independent assessor
progress of these 12 patients is described on page 8. (Dr Raj Narain) as having residual cavitation at
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1 year (cavitated series) and 126 as having no
residual cavitation (non-cavitated series). The pro-
gress of these 180 patients is now considered.
DEATHS
Altogether, 6 patients died during the 4-year
period of follow-up. One patient (H, non-cavitated,
placebo), who had a bacteriological relapse in the
twentieth month, died from tuberculous meningitis
in the forty-fifth month (see page 6). The remaining
5 patients died from non-tuberculous causes; 1 (HI-1,
non-cavitated, isoniazid) died in the twenty-third
month from diarrhoea with oedema, another (PH,
cavitated, isoniazid) died in the twenty-eighth month
following a cerebrovascular accident, another (PH,
non-cavitated, placebo) committed suicide in the thir-
tieth month, a fourth (HI-l, cavitated, placebo) died
in the forty-eighth month from cor pulmonale, and the
fifth (H, non-cavitated, placebo), who was known to
have bronchiectasis, died in the fifty-second month
from repeated large haemoptyses associated with it.
These 5 patients had had all cultures negative for
at least 12 months immediately preceding death.
BACTERIOLOGICAL RELAPSE IN THE
4-YEAR PERIOD OF FOLLOW-UP
During the 4-year period of follow-up, 17 (9.4%)
of the 180 patients had a bacteriological relapse,
10 (5.6%) in the second year (that is, the first year
of follow-up), 2 (1.1 %) in the third, 3 (1.7%) in the
fourth and 2 (1.1%) in the fifth year (Table 3).
Thus, the risk of relapse was greatest in the second
year.
Table 3 also presents the number of bacteriological
relapses, year by year, according to:
(1) the chemotherapy in the first year (PH, HI-I,
HI-2 or H);
(2) the cavitation status at the end of the first
year (cavitated or non-cavitated); and
(3) the treatment in the second year (placebo or
isoniazid).
The series in (1), in (2) and in (3) were compared
for the condition on admission to initial treatment,
and the condition at the end of the first year-that
is, the starting point of the study of relapse. The
findings have been reported earlier by Velu et al.
(1961a); in brief, the series were similar, both
initially and at 1 year, apart from the following
exceptions: (1) the PH and the HI-1 series contained
a higher proportion of patients who had larger
lesions initially than did the HI-2 and the H series;
(2) the PH, HI-1 and H patients had, on average,
rather more extensive residual radiographic lesions
at 1 year than the HI-2 patients; (3) the patients
with cavitation at 1 year had, on average, more
extensive radiographic lesions, both initially and at
TABLE 3
BACTERIOLOGICAL RELAPSE DURING THE 4-YEAR PERIOD OF FOLLOW-UP, RELATED TO CHEMOTHERAPY
IN THE FIRST YEAR, CAVITATION STATUS AT 1 YEAR AND TREATMENT IN THE SECOND YEAR
I Patients who had a bacteriological relapse
Year of relapse
%
Second  Third  Fourth  Fifth
PH 69 9 13 5 1 1 2
Chemotherapy in HI-1 41 3 7 2 0 1 0
the first year
HI-2 36 2 6 2 0 0 0
All patients  180  17 9.4  10  2  3  2
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1 year, than those without cavitation. Considering
next the intensity with which patients were examined
bacteriologically during the 4-year period of follow-
up, analyses (not presented here) showed that it
was broadly similar for the different series,
The proportions of patients who had a bacteriolo-
gical relapse during the 4-year period were 13% of
69 PH, 7% of 41 HI-1, 6% of 36 HI-2 and 9% of
34 H patients (Table 3); none of the differences
was significant (P > 0.4). Of 54 patients with cavita-
tion at 1 year, 11% had a bacteriological relapse
as compared with 9% of 126 patients with no
cavitation. Finally, 17% of 87 patients in the
placebo group had a bacteriological relapse as com-
pared with 2% of 93 patients in the isoniazid
group-a highly significant difference (P = 0.001).
Further analyses were undertaken to examine
whether, as in a previous report (Velu et al., 1961a),
the benefit from isoniazid in the second year was
greater in the patients with no cavitation at 1 year
than in those with cavitation. It was found that in
the patients with residual cavitation, 5 (23%) of 22
in the placebo group had a bacteriological relapse
as compared with 1 (3%) of 32 in the isoniazid
group (P=0.07). In the patients with no cavitation
at 1 year, 10 (15%) of 65 in the placebo group had
a bacteriological relapse as compared with 1 (2%)
of 61 in the isoniazid group, a highly significant
difference (P=0.01).
In summary, the bacteriological relapse rate over
the 4-year period did not appear to be influenced
either by the chemotherapy in the first year or the
cavitation status at 1 year. However, it was sub-
stantially lower in patients who received isoniazid
in the second year than in those who received the
placebo.
ISONIAZID ALONE IN THE THIRD YEAR
Of 93 patients who had received isoniazid alone
during the second year, 1 died and 1 had a bacterio-
logical relapse in the second year; the remaining 91
were allocated at random to treatment in the third
year, 44 to placebo and 47 to isoniazid alone.
The intensity of bacteriological examination dur-
ing the third, fourth and fifth years was similar
for the 2 groups. During this period, there were no
bacteriological relapses among the 44 patients in the
placebo group as compared with 1 among the 47
in the isoniazid group; this patient (Table 4, A285)
had a bacteriological relapse with isoniazid-resistant
organisms in the fifty-fourth month.
DETAILS OF PATIENTS WHO HAD
A BACTERIOLOGICAL RELAPSE
Table 4 gives the details for all the 17 patients who
had a bacteriological relapse during the 4-year
period. Clear-cut radiographic deterioration, con-
firmed by the independent assessor (Dr K. S. San-
jivi), occurred in 7.
Of the 17 patients, only 1 (A229) was receiving
isoniazid at the time of the relapse; she had
isoniazid-resistant organisms at the time of relapse.
Of the remaining 16 (none of whom was receiving
isoniazid at the time of the relapse), 12 yielded only
isoniazid-sensitive cultures during the period of
follow-up. Three patients (A229, A61, A20) had
excreted isoniazid-resistant organisms during the
first year; it is of interest that 2 of them had a
relapse with isoniazid-sensitive organisms.
In all, 11 of the 17 patients were re-treated. Six of
these, all of whom had a relapse with isoniazid-
sensitive cultures, were re-treated with isoniazid
plus PAS; 4 had bacteriologically quiescent disease
at 5 years. Four patients were re-treated with
streptomycin plus pyrazinamide, and all  had
quiescent disease at 5 years, and the remaining 2 had
bacteriologically active disease. The eleventh patient
was re-treated with streptomycin plus PAS and had
only negative cultures from the second month
onwards; however, 6 weeks after he had completed
a year of re-treatment, he developed tuberculous
meningitis and died 3 days after admission to a
general hospital.
Considering the 6 patients who were not re-treated,
the sputum became culture-negative spontaneously
in 3 (A146, A61, A275) after 16, 2 and 5 months,
respectively, and except for an isolated positive
culture in 1 patient (A275), remained consistently
negative up to 5 years. A fourth patient (All) had
a relapse in the fourth year and then produced a
series of negative cultures followed by positive cul-
tures late in the fifth year. The remaining 2 (A31,
A285) had a relapse in the fifth year, the second
positive culture occurring at about 60 months.
In summary, of the 17 patients who had a bac-
teriological relapse, 11 had bacteriologically quies-
cent disease at 5 years, 5 had bacteriologically active
disease and 1 had died from tuberculous meningitis.
VARIOUS FACTORS IN RELATION TO THE
OCCURRENCE OF BACTERIOLOGICAL RELAPSE
The influence of various factors on the occurrence
of bacteriological relapse in the 4-year period was
TABLE 4
DETAILS OF PATIENTS WHO HAD A BACTERIOLOGICAL RELAPSE, THEIR SUBSEQUENT CHEMOTHERAPY AND DISEASE STATUS AT 5 YEARS
Serial
no.
A146
A19
A287
A141
A11
A 2 2 9  HI-2
Chemo-
therapy in
first year
PH
HI-1
PH
PH
HI-1
A61       
A156
A18         
A275
A38        
A20
A334
A 1 5 7  
A 2 6 8  
A31           
HI-1
PH
PH
HI-2
PH
H
H
H
PH
PH
A285  PH
Cavitation
status at
1 year
Cavitated
Cavitated
Cavitated
Cavitated
Cavitated
Cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Treatment
in the
second
year
Placebo
Placebo
Placebo
Placebo
Placebo
lsoniazid 14, 15, 19, 24
Placebo 14, 15
Placebo 18, 19
Placebo 18, 20, 22, 24
Placebo 19, 20, 23, 45
Placebo 20-22
Placebo 20-24, 27-31
Placebo 36, 39, 42, 45-47
Placebo 17, 39, 42, 44, 45, 47
Placebo 45, 46
Placebo 54, 60
lsoniazid
Months at which 1 or
more positive cultures
were produced a
19-24, 30, 34
23-25
24, 27, 28
36, 39, 42
42, 45, 57, 59½, 60
54, 59½
Total no.
of positive
cultures a
Results of
isoniazid
sensitivity
tests b
1 1 All R
6 All S
6 All S
6 All S
6 S, R, S, S, S
6 All R
2 Both S
3 Both S
8 All S
4 All S
7 S, C, S
15 All S
9 S, N, S, S, S, S
8 All S
3 R, S
3 Both S
2 Both R
Clear-cut
radio-
graphic
deteriora-
tion
No
No
Yes
Yes
No
Yes
No
Yes
Yes
No
Yes
No
No
No
Yes
No
No
a Up to start of re-treatment.
b S = sensitive; R = resistant; C = contaminated; N = not tested.
c H = isoniazid; P = PAS; S = streptomycin; Z = pyrazinamide; C = cycloserine; E = ethionamide.
Month
re-
treatment
started
Re-treatment
chemotherapy c
(months)
–
26
29
43
–
–
SZ (18)
PH (12)
PH (12)
–
26 SZ (13)
– –
19 SZ (18)
25 PH (11); SZ (6); CE (12)
– –
23 PH (14)
31 SP (12)
48 PH (12)
47 PH (12)
46 SZ (12)
– –
– –
- -
l
Disease status
at 5 years
Quiescent
Quiescent
Quiescent
Quiescent
Active
Quiescent
Quiescent
Quiescent
Active
Quiescent
Quiescent
Died of tuberc-
ulous meningitis
Active
Quiescent
Quiescent
Active
Active
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investigated. The degree of smear positivity, the
extent of cavitation and the radiographic extent of
disease on admission to treatment were not associated
with the likelihood of relapse, nor was there any asso-
ciation between the occurrence of relapse and the
month of sputum conversion in the first year, the
extent of cavitation at 1 year or the radiographic
extent of disease at 1 year.
PATIENTS WITH ISOLATED POSITIVE CULTURES
Isolated positive cultures (defined on page 3)
were produced by 29 patients, namely, 11 (16 %) of
the PH, 5 (12%) of the HI-1, 6 (17%) of the HI-2
and 7 (21%) of the H patients; the proportion was
15% for the patients with cavitation at 1 year as
compared with 17% for those without cavitation,
and 14% for the patients in the placebo group as
compared with 18 % for the patients in the isoniazid
group. None of the differences was statistically
significant.
In all, 31 isolated positive cultures were produced
by the 29 patients–8 in the second year, 8 in the
third year, 11 in the fourth year and 4 in the fifth
year. Of these, 18 were from sputum specimens,
2 of which had a positive smear result. Considering
all 31 cultures, the growth was a single colony in 12
and 2 colonies in 3; it was more than 100 colonies
in only 4 cultures. The organisms were sensitive to
isoniazid in 18 of 27 cultures tested (including 2 of
4 specimens produced while the patient was receiving
isoniazid). Three of the 29 patients had produced
isoniazid-resistant cultures in the first year; in 2,
the isolated positive culture was sensitive to isoniazid
and in the third, the test result was not available.
Finally, the occurrence of an isolated positive
culture did not carry an unfavourable prognosis.
Thus, only 1 (3 %) of the 29 patients with an isolated
positive culture had a bacteriological relapse sub-
sequently.
OTHER ASSESSMENTS OF PROGRESS
The findings of the radiographic assessments and
erythrocyte sedimentation rate (ESR) determina-
tions are presented below for the 157 patients who
had bacteriologically quiescent disease throughout
the period of follow-up (of the remaining 23 patients,
17 had a bacteriological relapse, 5 died of
non-tuberculous causes and 1 patient refused to
attend for assessment from the forty-fifth month
onwards).
Changes in radiographic appearances
An independent assessor (Dr Raj Narain) assessed
the over-all changes in radiographic appearances
between 12 and 24, 24 and 36, and 36 and 60 months,
by viewing standard postero-anterior radiographs.
Improvement was reported in 29 %, 25 % and 18 %
of the patients, respectively, including 27%, 25%
and 18 % in whom it was graded as slight. The cor-
responding proportions for radiographic deteriora-
tion were 19%, 9 % and 20%, including 17 %, 7%
and 17% in whom it was graded as slight.
Cavitation changes between 12 and 60 months
were assessed by the independent assessor using
standard radiographs and tomograms. There were
46 patients with cavitation at 1 year; it disappeared
by 5 years in 52%, decreased in 24%, remained
unchanged in 20% and increased in 4%. Of 111
patients with no cavitation at 1 year, 4 (4%) devel-
oped cavitation by 5 years.
Erythrocyte sedimentation rate
The ESR reading at 1 hour was measured on
admission to treatment and, in most patients, at 1,
2, 3 and 4 years. The proportion of patients who had
an elevated ESR (more than 10 mm) was 65% at
1 year, 46 % at 2, 61% at 3 and 54 % at 4 years. For
an ESR of 21 mm or more, the corresponding
proportions were 39%, 27 %, 36% and 32%, respec-
tively, and for 51 mm or more, 12%, 8 %, 11% and
10 %, respectively.
In summary, there was general improvement over
the 4-year period in the radiographic condition
of the patients with persisting bacteriologically
quiescent disease. However, minor radiographic
changes interpreted as slight deterioration and ele-
vated ESRs occurred in a fair proportion of these
patients.
PATIENTS NOT INCLUDED IN THE RELAPSE STUDY
Of the 11 patients not included in the random
allocation to treatment (see page 4), 6 (2 PH,
1 HI-1, 3H; 4 cavitated, 2 non-cavitated) continued
to receive the treatment that they had had during
the first year while the remaining 5 (2 PH, 1 HI-1,
1 HI-2, 1 H; 1 cavitated, 4 non-cavitated) received
the placebo in the second year. Two of these
patients had a bacteriological relapse. One patient
(H, cavitated, isoniazid) had a relapse with isoniazid-
resistant organisms in the fourteenth month; sub-
sequently, positive cultures were occasionally ob-
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tained until the twenty-ninth month (the patient and had bacteriologically quiescent disease at 5 years.
received isoniazid in the third year also), and there- One patient (PH, cavitated, placebo) developed
after, the cultures were persistently negative up to tuberculous lymphadenitis, which was confirmed
the end of the period of follow-up. The other (PH, bacteriologically in the thirty-ninth month. She was
non-cavitated, placebo) had a bacteriological relapse re-treated with isoniazid plus PAS; all her sputum
with isoniazid-sensitive cultures (in the seventeenth and laryngeal swab cultures during the 4-year period
month), was re-treated with isoniazid plus PAS, were negative.
IV. PATIENTS WITH DISEASE OF BACTERIOLOGICALLY DOUBTFUL STATUS
AT 1 YEAR
Altogether, 9 patients (4 PH, 4 HI-1, 1 HI-2) had a bacteriological relapse. This relapse occurred at
were classified as having disease of bacteriologically 17 months with isoniazid-resistant organisms; subse-
doubtful status at one year; 3 had cavitation and quently, the cultures were positive at 18, 20 and 22
6 had no residual cavitation at 1 year; 6 received months but were negative thereafter (the patient re-
the placebo and 3 received isoniazid in the second ceived isoniazid in the third year also), and the patient
year. Only 1 patient (HI-1, non-cavitated, isoniazid) had bacteriologically quiescent disease at 5 years.
V. PATIENTS WITH BACTERIOLOGICALLY ACTIVE DISEASE AT 1 YEAR
Table 5 presents information on 96 patients
(7 PH, 17 HI-1, 27 HI-2, 45 H) who had bacterio-
logically active disease at 1 year, including 35
(1 PH, 5 HI-1, 14 HI-2, 15 H) who had had their
chemotherapy changed during the first year on
account of deterioration. Of the latter 35 patients,
15 received 1 reserve regimen (streptomycin plus
pyrazinamide or streptomycin plus PAS), 7 received
2 reserve regimens (the second usually being cyclo-
serine plus ethionamide or cycloserine plus thioacet-
azone), and 13 received more than 2 reserve regimens.
At 5 years, 15 (43%) patients had bacteriologically
quiescent disease, 5 had bacteriologically active dis-
ease and 15 had died, 13 of tuberculosis and 2 of
non-tuberculous causes.
Of the remaining 61 patients with bacteriologically
active disease at 1 year, 58 continued on their
initially allocated chemotherapy, 2 received isoniazid
and 1 received the placebo. Of these, 33 (54%) had
a change of chemotherapy for deterioration in the
second year and 17 (28 %) had a change of chemo-
therapy (at 2 years in 13 of them) due to persistent
sputum positivity; their subsequent progress is de-
scribed below. The remaining 11 (18 %) patients had
a late sputum conversion (10 of them by the begin-
ning of the second year), without receiving any
reserve regimen.
Of the 33 patients who had a deterioration in the
second year, 25 received 1 reserve regimen, 5 received
2 and 3 received 3. At 5 years, 27 (82%) patients
had bacteriologically quiescent disease, 3 had bacte-
riologically active disease and 3 had died, 2 of tuber-
culosis and 1 of a non-tuberculous cause.
Of the 17 patients who had a change of chemo-
therapy due to persistent sputum positivity, 13
received 1 reserve regimen and 3 received 2; the
remaining patient, who discharged himself, received
streptomycin plus isoniazid elsewhere. At 5 years,
12 (71%) patients had bacteriologically quiescent
disease, 2 had bacteriologically active disease and 3
had died, 2 of tuberculosis and 1 of a non-tuber-
culous cause.
Patients who had a deterioration in the first year
had a worse response subsequently than those who
had a deterioration in the second year, for 13 (37 %)
of 35 among the former died of tuberculosis as
compared with 2 (6%) of 33 among the latter,
a significant difference (P<0.01). However, the
bacteriological and radiographic 1 condition at the
time of the deterioration was worse for the patients
1 The radiographs for the two groups were assessed con-
currently by an independent assessor (Dr Raj Narain), in a
random order.
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TABLE 5
DISEASE STATUS AT 5 YEARS FOR PATIENTS WITH BACTERIOLOGICALLY ACTIVE DISEASE AT 1 YEAR
Disease status at 5 years
Quiescent
 Act ive
Death
No. % 
Non-
Tuberculous tuberculous
Deterioration in the first year 15 43        
 5
13 2
2 1
2 d 1
0 0
17 4
Change of
chemotherapy Deterioration in the second year 27 
a 3
Persistent sputum positivity 12b         (71)c                2       
I
No change of
chemotherapy Late sputum conversion
Total 65 68 10
a Including 1 patient who had a lobectomy.
b Including 1 patient who was treated in another institution and who also had a thoracoplasty.
c Parentheses indicate that the percentage is based on fewer than 25 observations.
d Including 1 patient whose chemotherapy was changed on account of cor pulmonale.
who had the deterioration in the first year than for
those who had the deterioration in the second year.
Thus, (1) 80 % of the former had a 2+ or 3 + smear
result as compared with 58 % of the latter (P=0.08);
(2) 66% and 27%, respectively, had moderate or
extensive cavitation (P <0.01); (3) 66% and 18 %,
respectively, had 5 or 6 lung zones involved (P<
0.001); (4) 63 % and 18 %, respectively, had moder-
ate, extensive or gross disease (P<0.001); and
(5) 31 % and 6%, respectively, had moderate or
considerable radiographic deterioration 1 in the
month just preceding the change of chemotherapy
(P = 0.02). Furthermore, analyses not tabulated here
showed that the patients in the categories (1), (2), (3),
(4) and (5) had a relatively unfavourable prognosis.
Finally, 8 of the patients who had the deterioration
in the first year received a regimen of cycloserine
plus thioacetazone which was rather ineffective
(Angel et al., 1963), as compared with none of the
patients who had the deterioration in the second
year. It may therefore be concluded that the substan-
tially worse response among the patients who
had the deterioration in the first year was due to
several factors.
VI. PATIENTS WHOSE TREATMENT WAS CHANGED FOR DRUG TOXICITY
DURING THE FIRST YEAR
Seven patients (1 PH, 5 HI-1, 1 HI-2) had their PAS and was prescribed streptomycin plus iso-
treatment changed in the first year due to drug niazid; the remaining 6 had peripheral neuropathy
toxicity. The PH patient had hypersensitivity to due to isoniazid and were prescribed a reserve
regimen (followed by a second reserve regimen in 2).
An eighth patient (PH) was successfully desensitized
1 The radiographs for the two groups were assessed con-
currently by an independent assessor (Dr Raj Narain), in a to PAS over a 3-month period. All 8 had bacterio-
random order. logically quiescent disease at 5 years.
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VII. PATIENTS EXCLUDED FROM THE MAIN ANALYSIS
Of the 26 patients excluded from the main ana-
lysis, 22 had isoniazid-resistant organisms on admis-
sion (acquired resistance in 2 and primary resistance
in 20). Considering first the 2 patients with acquired
isoniazid resistance, 1 died of a non-tuberculous
cause while under treatment with streptomycin plus
pyrazinamide, and the other had bacteriologically
active disease at 5 years despite receiving 2 reserve
regimens, namely, streptomycin plus pyrazinamide
and cycloserine plus ethionamide.
Of the 20 patients with primary isoniazid resis-
tance, 2 died of tuberculosis in the first year. Three
patients had bacteriologically quiescent disease at
1 year and maintained it up to 5 years, 2 having
received isoniazid alone in the second and third years
and 1 having received no chemotherapy after the
first year. Of the remaining 15 patients, all of whom
had bacteriologically active disease at 1 year, (1) 10
had bacteriologically quiescent disease at 5 years; of
these, 1 had received no reserve regimen, 7 had
received 1 reserve regimen, 1 had received 2 regimens,
and 1 had surgical collapse therapy in addition to
4 regimens; (2) 3 patients had bacteriologically active
disease at 5 years, despite 1 reserve regimen in 1 and
3 regimens in 2; and (3) 2 patients died of tubercu-
losis, 1 while receiving his first reserve regimen, and
the other, 13 months after discontinuing his second
reserve regimen.
In summary, 13 of 20 patients with primary
isoniazid resistance had bacteriologically quiescent
disease at 5 years, 3 had bacteriologically active
disease and 4 had died from tuberculosis.
Of 4 patients excluded from the main analysis
for miscellaneous reasons, 1 had died of a non-
tuberculous condition in the first year, and
the remaining 3 had bacteriologically quiescent
disease at 5 years without receiving any reserve
regimen.
VIII. DISEASE STATUS AT 5 YEARS OF ALL PATIENTS
The disease status at 5 years of the 96 PH, 75 HI-1,
75 HI-2 and 95 H patients is set out in Table 6.
During the 5-year period, 16 patients died of non-
tuberculous causes. Of these, 6 (2 PH, 1 HI-1,
1 HI-2, 2 H) died in the first year and have
been reported previously (Tuberculosis Chemo-
therapy Centre, Madras, 1960). Of the remaining
10 patients, 7 (2 PH, 2 HI-1, 3 H) had had all
cultures negative for at least 12 months be-
fore death; the other 3 (1 HI-1, 2 H) had become
culture-negative 1, 1 and 2 months, respectively,
before death.
One patient (HI-2) discharged himself from
follow-up in the forty-fifth month, having had all
cultures negative from the second month onwards;
he was known to be alive at 5 years.
Of the remaining 92 PH, 71 HI-1, 73 HI-2
and 88 H patients (including 21 of the 22 patients
with initial isoniazid resistance), 91%, 90%, 86%
and 76 %, respectively, had bacteriologically
quiescent disease at 5 years, 4%, 6%, 4% and 9 %
had bacteriologically active disease, and 4%,
4%, 10% and 15 %, respectively, had died of
tuberculosis. Considering all the patients in the
4 series combined, 86% of the patients had
bacteriologically quiescent disease at 5 years, 6%
had bacteriologically active disease and 8 % had died
of tuberculosis.
It will be recalled that the general policy was to
treat patients at home. In the event, 61 patients
(11 PH, 9 HI-1, 14 HI-2, 27 H), namely 18 %, were
hospitalized during the 5-year period for tuberculous
conditions, the period of hospitalization being
less than 1 month in 13, 1-3 months in 11, 3-6
months in 13, 6-12 months in 14 and 1 year or
more in 10.
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A previous communication from this Centre re-
ported on the progress during a 5-year period of
193 patients with newly diagnosed, bacteriologically
confirmed pulmonary tuberculosis, who were admit-
ted to a concurrent comparison of home and sana-
torium treatment for 1 year with isoniazid plus PAS
(Dawson et al., 1966). The present paper reports
on the progress, also over a 5-year period, of a
similar group of 341 patients, all of whom were
treated at home with isoniazid plus PAS or 1 of
3 regimens of isoniazid alone for a year. Since the
management of patients and the intensity of inves-
tigations in the 2 studies were practically identical,
it is convenient to review the findings of both studies
together.
The bacteriological relapse rate during the 4-year
period of follow-up (among those who had bacterio-
logically quiescent disease at 1 year) was 8.7 % of 126
in the earlier study and 9.4% of 180 in the presen-
study (it will be recalled that half the patients,
selected at random, received maintenance chemo-
therapy with isoniazid in the second year). There
was no evidence that the relapse rate was influenced
by the chemotherapeutic regimen received in the
first year; thus, for the isoniazid plus PAS regimen,
it was 8.7 % of 126 in the earlier study and 13 % of 69
in the present study (that is, 10% in both studies
combined), as compared with 7% of 41, 6% of 36
and 9% of 34 for the 3 regimens of isoniazid alone.
Isoniazid alone, given as maintenance therapy in
the second year, was highly effective in preventing
bacteriological relapse in patients who, at 1 year,
had bacteriologically quiescent disease and no resid-
ual cavitation. Thus, in the earlier study, none of 42
such patients had a bacteriological relapse in the
4-year period of follow-up as compared with 7
(17 %) of 42 who received a placebo, the correspond-
 ing proportions in the present study being 1 (2 %) of
61 and 10 (15 %) of 65, respectively. Both these
differences are significant (P=0.01). However, in
patients with residual cavitation at 1 year, the
benefit from isoniazid in the second year was less
marked. Thus, in the earlier study, 3 of 23 patients
who received isoniazid had a bacteriological relapse
in the 4-year period of follow-up as compared with
1 of 19 who received a placebo, the corresponding
proportions in the present study being 1 of 32 and 5
of 22, respectively. Combining the results of the
2 studies, 4 (7%) of 55 who received isoniazid had
a bacteriological relapse as compared with 6 (15 %)
of 41 who received a placebo (P=0.4).
In both studies, a subsidiary investigation, based
on random allocation, was undertaken to determine
the value of continuing isoniazid for the third year
in patients who had received isoniazid alone in the
second year. In the earlier study, there were no
bacteriological relapses in the third, fourth or fifth
years in 30 patients who received isoniazid in the
third year, but neither were there any relapses in
30 patients who received only a placebo in the
third year. The corresponding proportions in the
present study were 1 of 47 for the isoniazid group
and none of 44 for the placebo group. Thus, as there
were no relapses in either study in the patients who
had received a placebo in the third year, there was
really no scope for the isoniazid to prevent relapse.
(As far as we are aware, these 2 studies are the only
controlled investigations that compare the relative
merits of 1 year and 2 years of maintenance treat-
ment with isoniazid alone in the prevention of
relapse in patients with bacteriologically quiescent
disease at 1 year.) This finding emphasizes the need
to have suitable control groups for accurate inter-
pretation of the findings of chemotherapy studies
and, in particular, the need for caution in assessing
recommendations made by some workers for very
prolonged or indefinitely prolonged chemotherapy
to prevent relapse (Dooneief et al., 1955; Hyde,
1960; Pfuetze et al., 1960; Worobec et al., 1960).
For developing countries with limited resources,
the relapse rate in patients who received only 1 year
of antituberculosis chemotherapy is of special inter-
est. Of 148 such patients in the 2 studies combined,
23 (15.5%) had a bacteriological relapse during the
4-year period of follow-up. The relapse rate was
appreciable in the second year, namely, 9.5%, and
uniformly small in subsequent years, namely, 2.0 % in
the third, 2.0 % in the fourth and 2.0 % in the fifth year.
Further, it was unaffected by the cavitation status
of the patient at 1 year, 6 (15%) of 41 patients with
the “ open-negative ” syndrome having a bacteriolo-
gical relapse during the 4-year period, as compared
with 17 (16%) of 107 patients who had no residual
cavitation at 1 year, including 10 % and 9 %, respec-
tively, in the second year. These findings suggest
that, in countries with limited resources, long-term
follow-up beyond 2 years should be given a very
low level of priority, even if the patients have
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residual cavitation at 1 year. Further, of the relapses
in the second year, the great majority (11 of 14 in
the present report) can be detected by culture exam-
inations at 24 months, or earlier, if the patients
present with symptoms.
Isolated positive cultures, often with a growth of
only a few colonies and frequently isoniazid-sensi-
tive, occurred in the 4-year period of follow-up in
14% of the patients in the earlier study and 16%
of the patients in the present study. Their occurrence
is not very surprising (especially as the intensity
of bacteriological examination was high-namely,
over 40 cultures during the 4-year period) since,
even after prolonged and appropriate chemotherapy,
viable tubercle bacilli may be present in the lungs
(McDermott, 1959) and, indeed, in the sputum
(Great Britain, Medical Research Council, 1962).
Further, it was of little clinical importance, as only
6 % of such patients in the earlier study and 3 % in
the present study had a bacteriological relapse sub-
sequently. These findings suggest that chemotherapy
should not be restarted on the strength of a single posi-
tive culture, but should at least await 1 or more
confirmatory positive cultures within the next few
months.
An elevated ESR (that is, more than 10 mm)
was not uncommon in patients with bacteriolo-
gically quiescent disease throughout the 4-year period
of follow-up. Thus, the proportion of patients with
such a finding at the yearly examinations ranged
from 60 % to 75 % in the earlier study, and from
46% to 65% in the present study. These findings
demonstrate that measurements of ESR can often
be misleading in following the progress of patients
with bacteriologically quiescent disease. Similar
findings have also been reported from East Africa
(Hutton et al., 1956) and from the United Kingdom
(Great Britain, Medical Research Council, 1962).
In the treatment of patients with bacteriologically
active or relapsed disease with isoniazid-resistant
organisms, streptomycin plus pyrazinamide, strepto-
mycin plus PAS and cycloserine plus ethionamide
proved to be useful regimens (see Velu et al., 1960,
1961b, 1964; Angel et al., 1963; Ramakrishnan
et al., 1967).
Finally, considering the disease status at 5 years
of all the patients admitted to study (but excluding
deaths due to non-tuberculous causes), 90% in the
earlier study and 86% in the present study had
bacteriologically quiescent disease. These findings
are very encouraging, especially as nearly half the
patients (in the 2 studies combined) received isoniazid
alone as the primary regimen. Furthermore, the
follow-up in both studies was exceptionally good,
none of 193 patients in the earlier study and only 1
of 341 patients in the present study being per-
manently lost to observation. The remarkable degree
of success achieved in following the patients for
5 years was due to (1) the selection initially of
bona fide residents regarded as co-operative, (2) effi-
cient appointment systems, and (3) well-organized
domiciliary service.
In conclusion, the earlier study demonstrated
that patients with extensive sputum-positive tuber-
culosis, living in very adverse environmental, dietary
and economic conditions, can be treated success-
fully in their homes (Dawson et al., 1966; Rama-
krishnan et al., 1966). The present study has
provided confirmation of the value of well-organized
domiciliary chemotherapy.
X. SUMMARY
1. A total of 341 patients was admitted to a con- 3. Of the 315 patients, 192 had bacteriologically
trolled comparison of a standard oral regimen of quiescent disease at 1 year, 9 had disease of bacterio-
isoniazid plus PAS (PH) for 1 year with 3 oral logically doubtful status, 96 had bacteriologically
regimens of isoniazid alone, namely, 400 mg a day active disease, 10 had died (5 of tuberculosis and 5 of
in 1 dose (HI-1), 400 mg a day in 2, divided, doses non-tuberculous causes) and 8 had had their treat-
(HI-2), and 200 mg a day in 2, divided, doses (H). ment changed on account of drug toxicity.
4. Of the 192 patients with bacteriologically quies-
2. Of the 341 patients, 315 had isoniazid-sensitive cent disease at 1 year, 180 (69 PH, 41 HI-1, 36 HI-2,
cultures on admission and were included in the 34 H) were randomly allocated to treatment for
main analysis in the first year, and 26 were excluded the second year with isoniazid alone or a placebo;
because they did not conform to this or other of these 180 patients, 126 had no residual cavitation
important criteria. at 1 year.
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5. During the 4-year period of follow-up, 17
(9.4%) of the 180 patients had a bacteriological
relapse, 10 of them in the first year of follow-up.
The proportion with a relapse was 13% in the PH
series, as compared with 7 %, 6 % and 9% in the
HI-1, HI-2 and H series, respectively.
6. Of the 126 patients with no residual cavitation
at 1 year, 10 (15 %) of 65 in the placebo group had
a bacteriological relapse compared with 1 (2 %) of 61
in the isoniazid group (P=0.01). Of the 54 patients
with residual cavitation at 1 year, 5 (23 %) of 22 in
the placebo group had a bacteriological relapse
compared with 1 (3 %) of 32 in the isoniazid group
(P = 0.07).
7. A total of 91 patients, who had received iso-
niazid in the second year, were allocated at random
to treatment for the third year, 47 to isoniazid alone
and 44 to placebo; 1 and 0, respectively, had a
bacteriological relapse during the third, fourth or
fifth years.
8. Of 29 (16%) patients who produced isolated
positive cultures during the 4-year period of follow-
up, only 1 had a bacteriological relapse subsequently.
9. Of the 9 patients with disease of bacteriologi-
cally doubtful status at 1 year, 1 patient had a
bacteriological relapse, in the seventeenth month.
10. Of the 96 patients in the main analysis who
had bacteriologically active disease at 1 year, 84 were
re-treated with 1 or more reserve regimens. At
5 years, 65 (68%) of the 96 patients had bacteriolo-
gically quiescent disease, 10 (10%) had bacteriologi-
cally active disease, and 21 had died, 17 (18 %) from
tuberculosis and 4 (4%) from non-tuberculous
causes.
11. Of 20 patients excluded from the main ana-
lysis because they had primary isoniazid resistance
organisms, 13 (65 %) had bacteriologically quiescent
disease at 5 years, 3 had bacteriologically active
disease and 4 had died from tuberculosis.
12. Of the total of 341 patients admitted to the
study, 16 died from non-tuberculous causes during
the 5-year period and 1 took his discharge pre-
maturely. Of the remaining 324, 86 % had bacterio-
logically quiescent disease at 5 years, 6% had
bacteriologically active disease and 8% had died
of tuberculosis.
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RÉSUMÉ
ÉTUDE COMPARATIVE CONTRÔLÉE DU TRAITEMENT À DOMICILE DE LA TUBERCULOSE PULMONAIRE
PAR L’ASSOCIATION ISONIAZIDE-PAS OU PAR L’ISONIAZIDE SEUL SELON TROIS SCHÉMAS
DIFFÉRENTS: ANALYSE DE L’ÉVOLUTION CHEZ DES PATIENTS SUIVIS PENDANT CINQ ANS
Au cours d’une etude comparative de divers traitements
de la tuberculose pulmonaire, on a administré sous
contrôle, pendant un an, à un groupe de 341 malades
soit le schéma standard (PH) comportant en deux doses
quotidiennes 200 mg d’isoniazide et 10 g de PAS, soit
de l’isoniazide seul à raison de 400 mg par jour en une
dose unique (schema HI-l), de 400 mg par jour en deux
doses (schema HI-2) ou de 200 mg par jour en deux
doses (schema H). Sur ces 341 malades, 315 qui étaient
porteurs avant le traitement de bacilles sensibles à l’iso-
niazide ont été inclus dans l’enquête principale de la
1re année; 26 sujets en ont été éliminés pour resistance
à l’isoniazide ou pour d’autres raisons.
Sur ces 315 malades, 192 présentaient après un an
une affection bactériologiquement non évolutive; chez
9 autres, les examens bactériologiques donnaient des
résultats d’interpretation malaisée; 96 cas enfin étaient
bactériologiquement actifs. Dix déces ont été enregistrés
(5 dus à la tuberculose, 5 dus à d’autres causes). Chez
8 malades, on a modifié le traitement en raison de la
toxicité des médicaments.
Cent quatre-vingts des 192 malades qui ne montraient
aucun signe bactériologique d’évolution après un an,
soit 69 PH, 41 HI-1, 36 HI-2 et 34 H, ont été traités sur
une base aléatoire pendant Ia 2e année par l’isoniazide
seul ou par placebo. Sur ces 180 malades, 126 ne présen-
taient après la 1re année de traitement aucune cavité rési-
duelle. Au cours des 4 années suivant la 1re année de trai-
tement, 17 (9,4 %) des 180 patients ont présenté une rechute
bactériologique (deux cultures positives, ou davantage, au
cours d’une période de 6 mois), survenue chez 10 d’entre
eux, dans l’année suivant le traitement. La proportion des
rechutes a été de 13 % dans le groupe PH et de 7%, 6%
et 9 % respectivement dans les groupes HI-1, HI-2 et H.
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Parmi les 126 malades chez lesquels ne persistait après
un an de traitement aucune cavité résiduelle, 10 (15 %)
des 65 malades appartenant au groupe placebo ont
souffert d’une rechute bactériologique, alors qu’une telle
rechute n’a été observée que chez un seul (2%) des
61 malades traités par l’isoniazide (P=0,01). Sur les
54 patients qui, après un an, présentaient des cavités
residuelles, 5 (23%) des 22 malades du groupe placebo
ont eu une rechute bactériologique, qui ne s’est produite
que chez 1 (3%) des 32 malades du groupe traité par
l’isoniazide (P=0,07).
Un total de 91 malades traités par l’isoniazide pendant
Ia 2e année ont reçu par randomisation au cours de la
3e année soit de l’isoniazide seul (47 sujets) soit un pla-
cebo (44 sujets). On a enregistré dans ces groupes respec-
tivement 1 et 0 rechute bactériologique au cours de
Ia 3e, de la 4e ou de la 5e année de surveillance de
l’évolution.
Sur les 29 (16%) malades qui ont présenté une culture
positive isolée (c’est-à-dire avec négativite des cultures
6 mois avant et 6 mois après cet examen positif), au cours
des quatre années de surveillance après traitement, une
seule rechute bactériologique a été enregistrée par la suite.
Un seul des 9 cas « douteux » du point de vue bacté-
riologique a eu une rechute bactériologique au 17e mois.
Quatre-vingt quatre des 96 malades inclus dans l’etude
principale chez qui on décelait après un an une affection
bactériologiquement Obvolutive ont bénéficié d’un nou-
veau traitement suivant un ou plusieurs schémas non
encore utilisés. Après 5 ans, 65 (68%) de ces 96 malades
présentaient une affection bactériologiquement non évo-
lutive et 10 (10%) une tuberculose bactériologiquement
active. 11 s’etait produit 21 décès dont 17 (18%) dus à
la tuberculose et 4 (4 %) causes par d’autres maladies.
Parmi les 20 malades exclus de l’étude principale pour
resistance primaire à l’isoniazide, 13 (65 %) présentaient
après 5 ans une affection bactériologiquement non évolu-
tive et 3 une affection bactériologiquement active. Il y a
eu 4 décès par tuberculose.
Sur le total de 341 patients inclus dans l’étude, 16 sont
morts d’affections autres que la tuberculose au cours de
la période de 5 ans et 1 a cessé prématurément son trai-
tement. Après 5 ans, sur les 324 malades restants, 86%
présentaient une affection bactériologiquement non évo-
lutive et 6 % une tuberculose en evolution. On a enregistre
8% de décès par tuberculose.
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